Russo Daniele, Di Filippo Paola, Di Pillo Sabrina, Chiarelli Francesco, Attanasi Marina
Department of Pediatrics, University of Chieti, 66100 Chieti, Italy.
Biomedicines. 2023 Jan 17;11(2):236. doi: 10.3390/biomedicines11020236.
Asthma, chronic urticaria, and atopic dermatitis are some of the most numerous allergic diseases affecting children. Recent advances in the understanding of their specific intracellular molecular pathways have led to the approval of monoclonal antibodies targeting definite inflammatory molecules in order to control symptoms and improve quality of life. Less is known about other allergic and immunologic disorders such as rhinosinusitis with nasal polyps, eosinophilic esophagitis, anaphylaxis, and food allergy undergoing allergen immunotherapy. The increasing evidence of the molecular mechanisms underlying their pathogeneses made it possible to find in children new indications for known biological drugs, such as omalizumab and dupilumab, and to develop other ones even more specific. Promising results were recently obtained, although few are currently approved in the pediatric population. In this review, we aim to provide the latest evidence about the role, safety, and efficacy of biologic agents to treat allergic and immunologic diseases in children.
哮喘、慢性荨麻疹和特应性皮炎是影响儿童的最为常见的一些过敏性疾病。在对其特定细胞内分子途径的理解方面取得的最新进展，已促使靶向特定炎症分子的单克隆抗体获批，以控制症状并改善生活质量。对于其他过敏性和免疫性疾病，如伴有鼻息肉的鼻-鼻窦炎、嗜酸性食管炎、过敏反应以及正在接受变应原免疫治疗的食物过敏，人们了解得较少。越来越多的证据表明其发病机制背后的分子机制，使得在儿童中发现已知生物药物（如奥马珠单抗和度普利尤单抗）的新适应症并研发其他更具特异性的药物成为可能。尽管目前在儿科人群中获批的药物很少，但最近已取得了有前景的结果。在本综述中，我们旨在提供关于生物制剂在治疗儿童过敏性和免疫性疾病中的作用、安全性和疗效的最新证据。
